抑制NR2F2可以恢复激素治疗对内分泌耐受性乳腺癌的反应
Yanyan Cai1, Peihua Zhao2,3, Fan Wu1
1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Science translational medicine
|June 4, 2025
概括
神经纤维素1 (NF1) 的损失导致雌激素受体阳性乳腺癌的内分泌耐药性,通过增加核受体亚家族2组F成员2 (NR2F2). 抑制NR2F2恢复了激素治疗的敏感性,提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 内分泌学 在内分泌学.
背景情况:
- 内分泌抵抗是雌激素受体阳性 (ER+) 乳腺癌治疗的一个主要挑战.
- 身体突变,如神经纤维素1 (NF1) 损失,有助于内分泌抵抗,但潜在的机制仍然不清楚.
- 理解这些机制对于开发有效的内分泌疗法至关重要.
研究的目的:
- 阐明NF1损失诱导ER+乳腺癌内分泌抵抗的机制.
- 确定克服内分泌抵抗的新型治疗点.
主要方法:
- 使用CRISPR-Cas9淘汰屏幕识别了对NF1损失诱导的内分泌抵抗至关重要的基因.
- 机理学研究涉及分析核受体亚家族2组F成员2 (NR2F2) 在调节雌激素受体 (ER) 转录程序中的作用.
- 实验包括细胞系模型,患者衍生异体移植和基于器官的异体移植.
主要成果:
- 在CRISPR-Cas9查中,NR2F2被确定为NF1损失引起的内分泌抵抗的关键.
- NF1损失激活了线粒激活蛋白激酶 (MAPK) 途径,导致NR2F2诱导.
- 增加的NR2F2抑制了ER转录程序,通过改变ER细胞组,核心调节器平衡和染色质可访问性来抑制ER转录程序.
- 在具有各种抗性机制 (NF1,ARID1A,PTEN损失,KRAS过度表达) 的模型中,NR2F2的减少或抑制恢复了对激素治疗的敏感性.
结论:
- NR2F2是ER+乳腺癌内分泌抵抗的关键调解者,由MAPK通路激活驱动.
- 抑制NR2F2是一种有前途的治疗策略,可以克服各种内分泌抵抗机制.
- 向NR2F2可以提高乳腺癌患者内分泌治疗的疗效.
相关概念视频
Transducer Mechanism: Nuclear Receptors
2.4K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.4K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Target Cell Response to Hormones
5.2K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
5.2K
Receptor Downregulation in MVBs
2.8K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.8K
NF-κB-dependent Signaling Pathway
9.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.8K


